Divya Koura is an Oncology physician affiliated with University of San Diego. OpenAlex indexes 63 publications with 1,407 citations (h-index 15); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
10710 N Torrey Pines Rd
La Jolla, CA 920371035
Telephone
858-554-8788Provider last certified this registry record 12 Sept 2025.
Clinical trials
- Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
Sponsor: Dimitrios Tzachanis, MD PhD
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20256 payments
- AstraZeneca Pharmaceuticals LPProgram year20252 payments
- GlaxoSmithKline, LLC.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
24.5%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor24.5%Acyclovir100%Part D≥29 patientsCancer & immunology
23.5%Kinase inhibitor17.6%Jakafi43%Iclusig35%Brukinsa23%Part D<11 patientsThalidomide Analog3.2%Revlimid100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
14.6%Corticosteroid5.9%Prednisone100%Part D<11 patientsH2 blocker4.3%Famotidine100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NCCN Guidelines® Insights: Survivorship, Version 2.2025
Journal of the National Comprehensive Cancer Network
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Victor Nizet, MD
University of San Diego
Christopher Kane, MD
University of San Diego
Lawrence Marshall, MD
University of San Diego
Lyudmila Bazhenova, MD
University of San Diego
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”